PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+18.83%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$2.67B
AUM Growth
+$2.67B
(-5.5%)
Cap. Flow
-$524M
Cap. Flow
% of AUM
-19.65%
Top 10 Holdings %
Top 10 Hldgs %
54.89%
Holding
105
New
17
Increased
12
Reduced
35
Closed
21
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$166M |
| 2 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$44.4M |
| 3 |
Roivant Sciences
ROIV
|
$37.5M |
| 4 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$29.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
$19.5M |
Top Sells
| 1 |
Lyra Therapeutics
LYRA
|
$112M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$104M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$99.9M |
| 4 |
Soleno Therapeutics
SLNO
|
$90.2M |
| 5 |
Amicus Therapeutics
FOLD
|
$80.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAI
26
Caris Life Sciences, Inc. Common Stock
CAI
$10.8B
| $29.3M | 1.09% | +1,098,163 | New | +$29.3M |
|
27
Intuitive Surgical
ISRG
$170B
| $24.5M | 0.91% | 45,119 +4,500 | +11% | +$2.45M |
|
28
ADMA Biologics
ADMA
$4.12B
| $23.7M | 0.88% | 1,303,468 -69,765 | -5% | -$1.27M |
|
|
BBNX
29
Beta Bionics, Inc. Common Stock
BBNX
$819M
| $23.2M | 0.86% | 1,593,608 | – | – |
|
30
Spyre Therapeutics
SYRE
$996M
| $22.9M | 0.85% | 1,529,445 -783,827 | -34% | -$11.7M |
|
31
Evolus
EOLS
$494M
| $22.8M | 0.85% | 2,474,843 -1,654,299 | -40% | -$15.2M |
|
32
Celcuity
CELC
$2.17B
| $21.8M | 0.81% | 1,633,208 -729,071 | -31% | -$9.73M |
|
33
Dyne Therapeutics
DYN
$1.92B
| $21.4M | 0.79% | 2,247,390 -66,013 | -3% | -$628K |
|
|
SION
34
Sionna Therapeutics, Inc. Common Stock
SION
$1.09B
| $21.1M | 0.78% | 1,216,045 -35,056 | -3% | -$608K |
|
35
Axsome Therapeutics
AXSM
$6.05B
| $20.7M | 0.77% | 198,534 -156,573 | -44% | -$16.3M |
|
36
Repligen
RGEN
$6.88B
| $20.6M | 0.77% | 166,000 +36,199 | +28% | +$4.5M |
|
37
Insulet
PODD
$23.9B
| $19M | 0.7% | 60,387 -11,210 | -16% | -$3.52M |
|
38
Outset Medical
OM
$247M
| $16M | 0.59% | 833,333 | – | – |
|
39
Zymeworks
ZYME
$1.12B
| $16M | 0.59% | 1,275,274 -589,398 | -32% | -$7.4M |
|
40
CytomX Therapeutics
CTMX
$336M
| $15.9M | 0.59% | +6,993,646 | New | +$15.9M |
|
41
Aldeyra Therapeutics
ALDX
$351M
| $15.5M | 0.58% | 4,051,631 -5,224,220 | -56% | -$20M |
|
42
Charles River Laboratories
CRL
$8.04B
| $15.2M | 0.56% | +100,000 | New | +$15.2M |
|
|
CNTA
43
Centessa Pharmaceuticals
CNTA
$2.25B
| $15.1M | 0.56% | 1,146,935 -1,893,460 | -62% | -$24.9M |
|
44
Inhibrx
INBX
$408M
| $14M | 0.52% | 977,892 -86,134 | -8% | -$1.23M |
|
|
ADGM
45
Adagio Medical Holdings, Inc Common Stock
ADGM
$24.8M
| $12.8M | 0.48% | 9,876,576 +64,157 | +0.7% | +$83.4K |
|
46
Nurix Therapeutics
NRIX
$714M
| $12.5M | 0.46% | 1,096,985 +799,432 | +269% | +$9.11M |
|
47
Travere Therapeutics
TVTX
$1.56B
| $12.3M | 0.46% | +834,252 | New | +$12.3M |
|
48
Orchestra BioMed
OBIO
$147M
| $12.3M | 0.46% | 4,592,556 | – | – |
|
|
DRUG
49
Bright Minds Biosciences
DRUG
$276M
| $11M | 0.41% | 420,690 -23,959 | -5% | -$626K |
|
50
Inhibikase Therapeutics
IKT
$134M
| $10.6M | 0.39% | 5,432,293 -492,707 | -8% | -$961K |
|